Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Equities researchers at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a report released on Thursday, March 20th. Zacks Research analyst R. Department expects that the company will post earnings per share of ($4.87) for the year. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.07) per share.
A number of other equities analysts have also issued reports on NTLA. JPMorgan Chase & Co. restated a "neutral" rating and issued a $13.00 target price (down previously from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a research note on Monday, March 3rd. The Goldman Sachs Group reiterated a "sell" rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research note on Friday, February 28th. Morgan Stanley lowered Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and reduced their price objective for the company from $56.00 to $11.00 in a research note on Monday, January 27th. Finally, Oppenheimer reduced their price objective on Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a research note on Monday, January 13th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.56.
View Our Latest Stock Report on Intellia Therapeutics
Shares of NTLA stock opened at $9.00 on Monday. The firm has a market capitalization of $931.65 million, a price-to-earnings ratio of -1.65 and a beta of 1.97. The business has a fifty day moving average of $10.09 and a 200 day moving average of $14.13. Intellia Therapeutics has a 1 year low of $8.30 and a 1 year high of $28.23.
In related news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 29,000 shares of company stock worth $352,551. Insiders own 3.20% of the company's stock.
Several institutional investors have recently bought and sold shares of the company. ARK Investment Management LLC boosted its holdings in Intellia Therapeutics by 2.3% in the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock worth $146,174,000 after buying an additional 280,946 shares during the last quarter. Vanguard Group Inc. lifted its stake in Intellia Therapeutics by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company's stock worth $118,816,000 after purchasing an additional 562,249 shares in the last quarter. State Street Corp lifted its stake in Intellia Therapeutics by 17.9% in the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company's stock worth $105,700,000 after purchasing an additional 780,754 shares in the last quarter. Regeneron Pharmaceuticals Inc. purchased a new position in Intellia Therapeutics in the 4th quarter worth approximately $43,177,000. Finally, Geode Capital Management LLC lifted its stake in Intellia Therapeutics by 2.0% in the 4th quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company's stock worth $27,865,000 after purchasing an additional 45,930 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.